Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Angiogenesis

• Publication date

  2014-07-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10456-014-9438-1PMID 25012543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variable Selection

  2019cited by this paper
• Genetic markers of bevacizumab-induced hypertension

  2014cited by this paper
• Markers of response for the antiangiogenic agent bevacizumab.

  2013cited by this paper
• Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy

  2013cited by this paper
• Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

  2013cited by this paper
• Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

  2013cited by this paper
• Predictive Biomarkers for Bevacizumab: Are We There Yet?

  2013cited by this paper
• Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

  2013cited by this paper
• Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

  2013cited by this paper
• Mapping cis- and trans-regulatory effects across multiple tissues in twins

  2012cited by this paper
• Hypoxia-inducible factors: crosstalk between inflammation and metabolism.

  2012cited by this paper
• Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models

  2012cited by this paper
• Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  2012cited by this paper
• Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

  2012cited by this paper
• VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

  2012cited by this paper
• Controlling escape from angiogenesis inhibitors

  2012cited by this paper
• Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration

  2012cited by this paper
• The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer

  2012cited by this paper
• Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer

  2011cited by this paper
• HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

  2011cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent.

  2011cited by this paper
• VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders

  2010cited by this paper
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

  2010cited by this paper
• Sequencing of 50 Human Exomes Reveals Adaptation to High Altitude

  2010cited by this paper
• Regularization Paths for Generalized Linear Models via Coordinate Descent.

  2010cited by this paper
• Genetic Evidence for High-Altitude Adaptation in Tibet

  2010cited by this paper
• Haploview: Visualization and analysis of SNP genotype data.

  2009cited by this paper
• Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

  2009cited by this paper
• Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer

  2009cited by this paper
• Marker selection for genetic case–control association studies

  2009cited by this paper
• Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599.

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• HIF2α reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Testing association of a pathway with survival using gene expression data

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• VEGF gene polymorphisms and susceptibility to rheumatoid arthritis.

  2004cited by this paper
• A global test for groups of genes: testing association with a clinical outcome

  2004cited by this paper
• VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

  2003cited by this paper
• Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.

  2002cited by this paper
• Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma

  2001cited by this paper
• The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages

  2000cited by this paper
• The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.

  2000cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Angiogenesis

  1993cited by this paper
• Bioinformatics Applications Note Genetics and Population Analysis Genevar: a Database and Java Application for the Analysis and Visualization of Snp-gene Associations in Eqtl Studies

  year unknowninfluential reference

• Relationship between the Expressions of PD-L1 and Tumour-Associated Fibroblasts in Gastric Cancer

  2025cites this paper
• Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients

  2024cites this paper
• CEBP-β and PLK1 as Potential Mediators of the Breast Cancer/Obesity Crosstalk: In Vitro and In Silico Analyses

  2023cites this paper
• Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma

  2022cites this paper
• c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

  2022cites this paper
• VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

  2022cites this paper
• An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas

  2022cites this paper
• Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes.

  2021cites this paper
• The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids

  2021cites this paper
• Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma

  2020cites this paper
• Therapeutic Targeting of the Colorectal Tumor Stroma.

  2020cites this paper
• Clinical strategies to inhibit tumor vascularization

  2020cites this paper
• Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

  2020cites this paper
• Linked-read Sequencing Analysis Reveals Tumor-specific Genome Variation Landscapes in Neurofibromatosis Type 2 (NF2) Patients.

  2019influential citation
• [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer

  2019cites this paper
• An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

  2019cites this paper
• Targeting Angiogenesis in Prostate Cancer

  2019cites this paper
• Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

  2019cites this paper
• Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies.

  2018cites this paper
• Identification of functional single nucleotide polymorphisms (SNPs) in High Risk-Human Papillomavirus (HR-HPV) related diseases

  2018cites this paper
• Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear‐Cell Renal‐Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors

  2018cites this paper
• Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy

  2018cites this paper
• Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

  2017cites this paper
• Bevacizumab‐induced hypertension: Clinical presentation and molecular understanding

  2017cites this paper
• The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer

  2017cites this paper
• Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

  2017cites this paper
• PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.

  2016cites this paper
• Ten years of anti-vascular endothelial growth factor therapy

  2016cites this paper
• Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.

  2016cites this paper
• Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.

  2016cites this paper
• Cross-talk between EPAS-1/HIF-2α and PXR signaling pathway regulates multi-drug resistance of stomach cancer cell.

  2016cites this paper
• Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism

  2016cites this paper
• Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

  2016cites this paper
• Anti-vascular endothelial growth factor therapy in breast cancer: game over?

  2015cites this paper
• The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives

  2015cites this paper
• Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

  2015influential citation
• The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy

  2015cites this paper
• Use of bevacizumab as a first-line treatment for metastatic breast cancer.

  2015cites this paper
• The genetic basis of intradural spinal tumors and its impact on clinical treatment.

  2015cites this paper
• Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma

  2015cites this paper
• Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.

  2015cites this paper
• Genetic variants and response to cancer treatments

  2015cites this paper
• Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice

  2015cites this paper
• RESEARCH HIGHLIGHT Open Access

  2015cites this paper
• Congrès de l’association américaine de recherche contre le cancer — AACR 2016

  2015cites this paper
• Congrès de l’association américaine de recherche contre le cancer — AACR 2015

  2015cites this paper
• Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

  2014cites this paper
• Bevacizumab: A Review of Its Use in Advanced Cancer

  2014cites this paper